Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire Launches Intuniv Tablets In US
Shire has launched Intuniv (guanfacine) extended release tablets in pharmacies across the US for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17.
Shire has launched Intuniv (guanfacine) extended release tablets in pharmacies across the US for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17.
Conceptus has reported that the US District Court, Northern District of California has denied Conceptus’ motion for a preliminary injunction prohibiting Hologic, from importing, using, selling or offering
Natrol has been recently certified by the Natural Products Association (NPA) current Good Manufacturing Practices (cGMP) certification program which incorporates the FDA final cGMP rule. Jenia Khudagulyan, senior
Qiagen has signed a definite agreement to acquire SABiosciences, a privately-held developer and manufacturer of disease- and pathway-focused PCR assay panels. The company said that transaction is valued
Eisai has reported that the novel once daily anti-epileptic Zebinix (eslicarbazepine acetate) has been launched in the UK as adjunctive therapy in adults with partial-onset seizures, with or
The company said that Zebinix (eslicarbazepine acetate) which was launched in 1965 offers patients seizure control. Patients also report improvements in health-related quality of life measures such as
Dyax will present an analysis demonstrating the ability of DX-88 (ecallantide) to resolve symptoms of acute hereditary angioedema (HAE) attacks in all anatomic locations. The analysis will be
Mindray will also present demonstration units of six new products for 2009, including a surgical bed, surgical light, ceiling pendent system, WATO EX 30 anesthesia machine, BC-5800 hematology
The US Patent and Trademark Office (USPTO) has issued a patent to BioMarin Pharmaceutical (BioMarin) covering the approved administration of Kuvan (sapropterin dihydrochloride) with food for the treatment
The topic for the Grand Challenge Grant is low cost diagnostics for global priory health conditions, which includes both malaria and tuberculosis. Clayton Hardman, CEO of Biomagnetics Diagnostics,